Paper41524971
AI-driven peptide discovery for endometrial cancer: deep generative modeling and molecular simulation in the big data era.
Fatima I and 8 others. J Comput Aided Mol Des, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. AI-driven peptide discovery for endometrial cancer: deep generative modeling and molecular simulation in the big data era. Papers, record 41524971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41524971
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- AI-driven peptide discovery for endometrial cancer: deep generative modeling and molecular simulation in the big data era.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endometrial Neoplasms | Major topic |
| Peptides | Major topic |
| Drug Discovery | Major topic |
| Artificial Intelligence | Major topic |
| Female | |
| Humans | |
| Generative Adversarial Networks | |
| Generative Artificial Intelligence | |
| Deep Learning | |
| Molecular Docking Simulation | |
| Autoencoder | |
| beta Catenin | |
| Reinforcement Machine Learning | |
| Proto-Oncogene Proteins c-akt | |
| Molecular Dynamics Simulation | |
| Drug Design |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 62072377 | National Natural Science Foundation of China | PubMed |
Source PubMed
References65
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32508653 | Discovering Anti-Cancer Drugs via Computational Methods. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32508653 | PubMed |
| 2 | 39605829 | Therapeutic peptide development revolutionized: Harnessing the power of artificial intelligence for drug discovery. | Heliyon | 2024 | https://conductscience.org/library/papers/39605829 | PubMed |
| 3 | 37337978 | FIGO staging of endometrial cancer: 2023. | Int J Gynaecol Obstet | 2023 | https://conductscience.org/library/papers/37337978 | PubMed |
| 4 | 33983732 | Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies. | J Med Chem | 2021 | https://conductscience.org/library/papers/33983732 | PubMed |
| 5 | 33507815 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33507815 | PubMed |
| 6 | 28822813 | Reinforcement learning-based control of drug dosing for cancer chemotherapy treatment. | Math Biosci | 2017 | https://conductscience.org/library/papers/28822813 | PubMed |
| 7 | 30096949 | Modeling Endometrial Cancer: Past, Present, and Future. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30096949 | PubMed |
| 8 | 39480053 | Beyond Conventional Drug Design: Exploring the Broad-Spectrum Efficacy of Antimicrobial Peptides. | Chem Biodivers | 2025 | https://conductscience.org/library/papers/39480053 | PubMed |
| 9 | 34531006 | Deep Reinforcement Learning for Fractionated Radiotherapy in Non-Small Cell Lung Carcinoma. | Artif Intell Med | 2021 | https://conductscience.org/library/papers/34531006 | PubMed |
| 10 | 36040035 | Arteannuin B Enhances the Effectiveness of Cisplatin in Non-Small Cell Lung Cancer by Regulating Connexin 43 and MAPK Pathway. | Am J Chin Med | 2022 | https://conductscience.org/library/papers/36040035 | PubMed |
| 11 | 32914015 | De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor. | JCO Precis Oncol | 2019 | https://conductscience.org/library/papers/32914015 | PubMed |
| 12 | 35936396 | A Generative Approach to Materials Discovery, Design, and Optimization. | ACS Omega | 2022 | https://conductscience.org/library/papers/35936396 | PubMed |
| 13 | 34393317 | Machine Learning in Drug Discovery: A Review. | Artif Intell Rev | 2022 | https://conductscience.org/library/papers/34393317 | PubMed |
| 14 | 40054129 | Controversies in the management of grade 1 and 2 endometrioid carcinoma of the ovary and uterus. | Int J Gynecol Cancer | 2025 | https://conductscience.org/library/papers/40054129 | PubMed |
| 15 | 34699719 | Generative Deep Learning for Targeted Compound Design. | J Chem Inf Model | 2021 | https://conductscience.org/library/papers/34699719 | PubMed |
| 16 | 35510835 | Reinforcement learning for systems pharmacology-oriented and personalized drug design. | Expert Opin Drug Discov | 2022 | https://conductscience.org/library/papers/35510835 | PubMed |
| 17 | 36093931 | Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and endometrial cancer risk: a multicentric case-control study. | Br J Nutr | 2023 | https://conductscience.org/library/papers/36093931 | PubMed |
| 18 | 28006993 | The structural modification of natural products for novel drug discovery. | Expert Opin Drug Discov | 2017 | https://conductscience.org/library/papers/28006993 | PubMed |
| 19 | 36158077 | Cisplatin for cancer therapy and overcoming chemoresistance. | Heliyon | 2022 | https://conductscience.org/library/papers/36158077 | PubMed |
| 20 | 35531470 | The Role of CTNNB1 in Endometrial Cancer. | Dis Markers | 2022 | https://conductscience.org/library/papers/35531470 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42366266 | Integrating artificial intelligence and multi-omics data for precision oncology in endometrial cancer: a narrative review. | Funct Integr Genomics | 2026 | https://conductscience.org/library/papers/42366266 | PubMed |
| 42099970 | Next-Generation Anticancer Peptides: Engineering, Nanotheranostics and Clinical Translation. | Nanotheranostics | 2026 | https://conductscience.org/library/papers/42099970 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| GJA1 | 2697 | PubTator's text mining | https://conductscience.org/library/genes/2697 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41524971
GET https://conductscience.org/api/papers/v1/41524971/references?page=2